LUGPA GU Oncology VL

Evolution of Technology and Technique in Bladder Cancer - Ashish Kamat

(Length of Discussion: 10 min) Ashish Kamat and Alicia Morgans discuss the highlights of his presentation at LUGPA 2018, on the evolution of technology and technique when treating bladder cancer. The initial resection of the bladder is paramount to the path of management for these patients, including the type of anesthesia, angles of scopes, white light and blue light detection, narrow-band imagin...

Focal Therapy: Ready or Not - Herbert Lepor

(Length of Discussion: 20 min) Herb Lepor presents the current optimal management of localized prostate cancer including an in-depth review of focal ablation. He highlights technique, criteria for appropriate patient selection, and the value of counseling to managing expectations. Biography: Herbert Lepor, MD, Professor, Department of Urology, Professor, Department of Biochemistry and Molecular Ph...

Minimally Invasive Approaches in the Treatment of BPH: Ready to Replace TURP? - Claus Roehrborn

(Length of Presentation: 26 min) Claus Roehrborn provides a state of the art review on contemporary management of male lower urinary tract symptoms (MLUTS) and BPH. Biography: Claus Roehrborn, MD is at the Harold C. Simmons Comprehensive Cancer Center. Dr. Roehrborn is the S.T. Harris Family Chair in Medical Science, in Honor of John D. McConnell, M.D. and the E.E. Fogelson and Greer Garson Fogels...

Immuno-Oncology: The Urologist's Role - Noah Hahn

(Length of Discussion: 20 min) Noah Hahn presents the importance of immuno-oncology (IO) and its role for early stage diseases such as non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). In addition, he discusses the ongoing studies in the IO space that can be practice changing in both NMIBC/MIBC. Biography: Noah M. Hahn, MD, Associate Professor of Medicine, Depar...

Genetic Evaluation of Hereditary Prostate Cancer - Sanjeev Kaul

(Length of Presentation: 27 min) Sanjeev Kaul discusses hereditary prostate cancer (HPC) and why HPC is important, which patients should be tested based on the NCCN guidelines and what tests are available. Also, presented is the process for clinic testing for HPC and the future directions in this field. Biography: Sanjeev Kaul, MD, M.CH, Comprehensive Urology, Associate Professor of Urology, Oakla...

Practice Changing Applications of Radiology and Nuclear Medicine in GU Malignancies- Phillip Koo

(Length of Discussion: 23 min) Phillip Koo presents practice changing applications of radiology and nuclear medicine in genitourinary malignancies. He reviews the disruption in radiology specifically, imaging modalities, teleradiology, and artificial intelligence and the impact these have on patient care. The value to the health care system incorporates quality of imaging as well as impact to outc...

Is There an Optimal TURBT Technique and the Color War? - Ashish Kamat

(Length of Discussion: 22 min) Ashish Kamat discusses the importance of TURBT and its value for diagnosis, therapeutic and prognostic purposes as an essential part of multidisciplinary care with specific regards to clinical trials. Ashish also compares different agents for the detection of bladder cancer and how these agents are reflected in the AUA/SUO Guidelines. Biography: Ashish Kamat, MD, MBB...

Technologies Related to Prostate Biopsies - David Crawford

(Length of Presentation: 19 min) David Crawford shares his perspective related to innovation in technology and the impact on medicine and clinical practice. His primary focus for review is prostate biopsies and the variety of influencers such as PSA, genomics, fusion biopsies, transrectal and micro-ultrasounds, D mapping, and electronic medical recording. Biography: E. David Crawford, MD, Professo...

When BCG Fails… Know All the Options - Gary Steinberg

When BCG Fails… Know All the Options Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of Presentation: 32 min) Gary Steinberg, MD overviews the history of BCG since the 1980’s and it being the chosen method of treatment regardless if the patient has low, intermediate or high risk disease. He highlights the number of patients receiving BCG, and maintenance is the same and his...

Practice Changing Events in Prostate Cancer- Charles Ryan

Practice Changing Events in Prostate Cancer, a Conversation with Alicia Morgans and Charles Ryan Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of Discussion: 14 min) Alicia Morgans, MD sits down with Charles Ryan, MD to discuss some of the practice changing events in prostate cancer and advanced prostate cancer in 2017. Some of the highlights they cover are the LATITUDE an...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.